KX826 New Phase 3 Trial In China for 2025: 1.0% concentration
    1/10/2025

    From the encyclopedia
    Finasteride →

    Popular 5-alpha reductase inhibitor that lowers DHT, taken as a pill or used topically

    Dutasteride →

    5-alpha reductase inhibitor that blocks both enzyme types, a stronger DHT blocker than finasteride

    At a glance
    In this research discussion post, the primary subjects mentioned are
    💧 KX-826 (topical) 1.0%
    the tone is 😐 neutral with varied opinions results.

    Other terms

    KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community 1 year on fin. No results. I give up.

      in Finasteride/Dutasteride  43 upvotes 3 years ago
      A user who has been taking finasteride, minoxidil, and microneedling for one year with no results, and the replies discuss other treatments, including dutasteride, which is feared due to potential side effects.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

       133 upvotes 2 years ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Been off Tressless for a few years - what’s the latest on GT20029?

       17 upvotes 1 month ago
      GT20029 is an experimental topical treatment for male-pattern hair loss, showing promising results in Phase 2 trials and moving towards Phase 3. It aims to degrade androgen receptors in hair follicles, differing from treatments like finasteride and minoxidil.

      community When is the cure gonna drop , how much more time

      in Research/Science  112 upvotes 7 months ago
      There is no imminent cure for hair loss, but treatments like Minoxidil, Finasteride, and new drugs such as KX-826, GT-20029, and PP405 are being explored. Current solutions focus on slowing hair loss and stimulating growth, with hopes for better options in the future.

    Related Research

    6 / 6 results

      research Androgenetic Alopecia: Therapy Update

      May 2023 in “Drugs”
      This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

      research The 100 most cited articles in androgenetic alopecia: A bibliometric analysis

      March 2025 in “Medicine”
      This study performed a bibliometric analysis of the 100 most cited articles on androgenetic alopecia from 1975 to 2024, revealing that U.S. authors contributed most and highlighting a trend toward research focused on treatment options, especially between 2020 and 2024.

      research A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies

      December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology”
      This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.